Cheplapharm Acquires Portfolio of 20 Medicines and Three Manufacturing Sites from Sanofi
Cheplapharm has entered into a strategic partnership with Sanofi to acquire a portfolio of 20 mature medicines, including Lovenox/Clexane (enoxaparin), along with three global manufacturing facilities. The deal includes production sites in Hungary, Singapore, and France, employing approximately 565 workers collectively. Sanofi will retain a 26.4% equity stake in Cheplapharm as part of the transaction. Both companies aim to maintain supply continuity during the transition period, which is expected to begin in Q1 2027 and conclude by Q3 2027 after regulatory approvals. The partnership builds on a decade-long collaboration between Sanofi and Cheplapharm, with both parties emphasizing that different operational models may better suit established treatments compared to innovative drugs. Thomas Grenier of Sanofi stated the move aligns with their strategy to focus more resources on innovation while ensuring continued access to essential medicines through trusted partners like Cheplapharm.
Tickers: $SNY